Chime Biologics

Chime Biologics is a leading Contract Development and Manufacturing Organization (CDMO) in the biopharmaceutical industry. Founded in 2013, the company operates with the slogan "Sound Solution for Manufacturing." Chime Biologics offers a comprehensive range of customer-centric and cost-effective services, spanning from analytical and process transfer to early-stage biopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for global supply. The company is headquartered in China and operates in the Biopharma, Biotechnology, Health Care, and Manufacturing sectors. Chime Biologics recently secured a noteworthy CNY17.40M Series B investment at 01 February 2023 from Panacea Venture. This investment signifies a strong show of support for the company's growth and development plans, underlining investor confidence in Chime Biologics' capabilities and market potential. Overall, Chime Biologics' seasoned expertise, coupled with its recent substantial investment, positions the company as a key player in the biopharmaceutical CDMO space, poised for continued success and impact in the global healthcare and manufacturing industries. For further details, visit www.chimebiologics.com.